Phenotype modulators in myophosphorylase deficiency

Andrea Martinuzzi, Elena Sartori, Marina Fanin, Annachiara Nascimbeni, Lucia Valente, Corrado Angelini, Gabriele Siciliano, Tiziana Mongini, Paola Tonin, Giuliano Tomelleri, Antonio Toscano, Luciano Merlini, Laurence A. Bindoff, Stefano Bertelli

Research output: Contribution to journalArticle

Abstract

Myophosphorylase deficiency is characterized by exercise intolerance, muscle cramps, and recurrent myoglobinuria. Some patients are severely affected, whereas others are minimally affected or asymptomatic. The molecular basis of the disease has been elucidated but does not provide an explanation for the clinical variability. In a large cohort of patients with myophosphorylase deficiency, we tested the hypothesis that polymorphic variants in either myoadenylate deaminase (MADA) or angiotensin-converting enzyme (ACE) could act as modulators of phenotype expression. Forty-seven patients were evaluated. Clinical severity was assessed according to a severity scale of four grades. MADA activity was studied by histochemical and biochemical analysis of muscle, and the Q12X mutation in the adenine monophosphate deaminase 1 gene (AMPDI) and the insertion/deletion polymorphism in the ACE gene were assessed genetically. A complete MADA defect together with the Q12X mutation was detected in one severely affected patient. Eleven patients were heterozygous for the Q12X mutation. There was no association between clinical grading and MADA status. In contrast, we found a highly significant (p <0.01) association between ACE genotype and clinical severity, with strong correlation between severe phenotype and number of D alleles. We show that ACE insertion/deletion polymorphism may play a significant role as phenotype modulator in McArdle's disease.

Original languageEnglish
Pages (from-to)497-502
Number of pages6
JournalAnnals of Neurology
Volume53
Issue number4
DOIs
Publication statusPublished - Apr 1 2003

Fingerprint

Glycogen Storage Disease Type V
AMP Deaminase
Peptidyl-Dipeptidase A
Phenotype
adenine deaminase
Mutation
Muscle Cramp
Insertional Mutagenesis
Gene Deletion
Alleles
Genotype
Exercise
Muscles
Genes

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Martinuzzi, A., Sartori, E., Fanin, M., Nascimbeni, A., Valente, L., Angelini, C., ... Bertelli, S. (2003). Phenotype modulators in myophosphorylase deficiency. Annals of Neurology, 53(4), 497-502. https://doi.org/10.1002/ana.10499

Phenotype modulators in myophosphorylase deficiency. / Martinuzzi, Andrea; Sartori, Elena; Fanin, Marina; Nascimbeni, Annachiara; Valente, Lucia; Angelini, Corrado; Siciliano, Gabriele; Mongini, Tiziana; Tonin, Paola; Tomelleri, Giuliano; Toscano, Antonio; Merlini, Luciano; Bindoff, Laurence A.; Bertelli, Stefano.

In: Annals of Neurology, Vol. 53, No. 4, 01.04.2003, p. 497-502.

Research output: Contribution to journalArticle

Martinuzzi, A, Sartori, E, Fanin, M, Nascimbeni, A, Valente, L, Angelini, C, Siciliano, G, Mongini, T, Tonin, P, Tomelleri, G, Toscano, A, Merlini, L, Bindoff, LA & Bertelli, S 2003, 'Phenotype modulators in myophosphorylase deficiency', Annals of Neurology, vol. 53, no. 4, pp. 497-502. https://doi.org/10.1002/ana.10499
Martinuzzi A, Sartori E, Fanin M, Nascimbeni A, Valente L, Angelini C et al. Phenotype modulators in myophosphorylase deficiency. Annals of Neurology. 2003 Apr 1;53(4):497-502. https://doi.org/10.1002/ana.10499
Martinuzzi, Andrea ; Sartori, Elena ; Fanin, Marina ; Nascimbeni, Annachiara ; Valente, Lucia ; Angelini, Corrado ; Siciliano, Gabriele ; Mongini, Tiziana ; Tonin, Paola ; Tomelleri, Giuliano ; Toscano, Antonio ; Merlini, Luciano ; Bindoff, Laurence A. ; Bertelli, Stefano. / Phenotype modulators in myophosphorylase deficiency. In: Annals of Neurology. 2003 ; Vol. 53, No. 4. pp. 497-502.
@article{10f830887261413b909951d09e242c03,
title = "Phenotype modulators in myophosphorylase deficiency",
abstract = "Myophosphorylase deficiency is characterized by exercise intolerance, muscle cramps, and recurrent myoglobinuria. Some patients are severely affected, whereas others are minimally affected or asymptomatic. The molecular basis of the disease has been elucidated but does not provide an explanation for the clinical variability. In a large cohort of patients with myophosphorylase deficiency, we tested the hypothesis that polymorphic variants in either myoadenylate deaminase (MADA) or angiotensin-converting enzyme (ACE) could act as modulators of phenotype expression. Forty-seven patients were evaluated. Clinical severity was assessed according to a severity scale of four grades. MADA activity was studied by histochemical and biochemical analysis of muscle, and the Q12X mutation in the adenine monophosphate deaminase 1 gene (AMPDI) and the insertion/deletion polymorphism in the ACE gene were assessed genetically. A complete MADA defect together with the Q12X mutation was detected in one severely affected patient. Eleven patients were heterozygous for the Q12X mutation. There was no association between clinical grading and MADA status. In contrast, we found a highly significant (p <0.01) association between ACE genotype and clinical severity, with strong correlation between severe phenotype and number of D alleles. We show that ACE insertion/deletion polymorphism may play a significant role as phenotype modulator in McArdle's disease.",
author = "Andrea Martinuzzi and Elena Sartori and Marina Fanin and Annachiara Nascimbeni and Lucia Valente and Corrado Angelini and Gabriele Siciliano and Tiziana Mongini and Paola Tonin and Giuliano Tomelleri and Antonio Toscano and Luciano Merlini and Bindoff, {Laurence A.} and Stefano Bertelli",
year = "2003",
month = "4",
day = "1",
doi = "10.1002/ana.10499",
language = "English",
volume = "53",
pages = "497--502",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Phenotype modulators in myophosphorylase deficiency

AU - Martinuzzi, Andrea

AU - Sartori, Elena

AU - Fanin, Marina

AU - Nascimbeni, Annachiara

AU - Valente, Lucia

AU - Angelini, Corrado

AU - Siciliano, Gabriele

AU - Mongini, Tiziana

AU - Tonin, Paola

AU - Tomelleri, Giuliano

AU - Toscano, Antonio

AU - Merlini, Luciano

AU - Bindoff, Laurence A.

AU - Bertelli, Stefano

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Myophosphorylase deficiency is characterized by exercise intolerance, muscle cramps, and recurrent myoglobinuria. Some patients are severely affected, whereas others are minimally affected or asymptomatic. The molecular basis of the disease has been elucidated but does not provide an explanation for the clinical variability. In a large cohort of patients with myophosphorylase deficiency, we tested the hypothesis that polymorphic variants in either myoadenylate deaminase (MADA) or angiotensin-converting enzyme (ACE) could act as modulators of phenotype expression. Forty-seven patients were evaluated. Clinical severity was assessed according to a severity scale of four grades. MADA activity was studied by histochemical and biochemical analysis of muscle, and the Q12X mutation in the adenine monophosphate deaminase 1 gene (AMPDI) and the insertion/deletion polymorphism in the ACE gene were assessed genetically. A complete MADA defect together with the Q12X mutation was detected in one severely affected patient. Eleven patients were heterozygous for the Q12X mutation. There was no association between clinical grading and MADA status. In contrast, we found a highly significant (p <0.01) association between ACE genotype and clinical severity, with strong correlation between severe phenotype and number of D alleles. We show that ACE insertion/deletion polymorphism may play a significant role as phenotype modulator in McArdle's disease.

AB - Myophosphorylase deficiency is characterized by exercise intolerance, muscle cramps, and recurrent myoglobinuria. Some patients are severely affected, whereas others are minimally affected or asymptomatic. The molecular basis of the disease has been elucidated but does not provide an explanation for the clinical variability. In a large cohort of patients with myophosphorylase deficiency, we tested the hypothesis that polymorphic variants in either myoadenylate deaminase (MADA) or angiotensin-converting enzyme (ACE) could act as modulators of phenotype expression. Forty-seven patients were evaluated. Clinical severity was assessed according to a severity scale of four grades. MADA activity was studied by histochemical and biochemical analysis of muscle, and the Q12X mutation in the adenine monophosphate deaminase 1 gene (AMPDI) and the insertion/deletion polymorphism in the ACE gene were assessed genetically. A complete MADA defect together with the Q12X mutation was detected in one severely affected patient. Eleven patients were heterozygous for the Q12X mutation. There was no association between clinical grading and MADA status. In contrast, we found a highly significant (p <0.01) association between ACE genotype and clinical severity, with strong correlation between severe phenotype and number of D alleles. We show that ACE insertion/deletion polymorphism may play a significant role as phenotype modulator in McArdle's disease.

UR - http://www.scopus.com/inward/record.url?scp=0037379666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037379666&partnerID=8YFLogxK

U2 - 10.1002/ana.10499

DO - 10.1002/ana.10499

M3 - Article

C2 - 12666117

AN - SCOPUS:0037379666

VL - 53

SP - 497

EP - 502

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -